Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sputum

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    624 result(s) found for: Sputum. Displaying page 9 of 32.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2010-023959-28 Sponsor Protocol Number: GS-US-219-0104 Start Date*: 2011-07-04
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solutio...
    Medical condition: Non-CF bronchiectasis and gram-negative endobronchial infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    14.1 10021881 - Infections and infestations 10070295 Infective exacerbation of bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005079-17 Sponsor Protocol Number: 06-IN-AK004 Start Date*: 2007-02-19
    Sponsor Name:Nektar Therapeutics
    Full Title: An Open-Label, Multicenter, Multinational Study to Assess the Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-Ventilated Patients with Nosocomial Pne...
    Medical condition: Nosocomial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052596 Nosocomial pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-001665-25 Sponsor Protocol Number: 1 Start Date*: 2018-10-23
    Sponsor Name:Erasmus MC
    Full Title: Formoterol-beclomethasone in patients with bronchiectasis: a randomized, double-blind, placebo-controlled trial (Forza study)
    Medical condition: Bronchiectasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003842-27 Sponsor Protocol Number: Studio-flourochinoloni-in-BPCO. Start Date*: 2008-10-14
    Sponsor Name:CENTRO STUDI FADOI
    Full Title: Randomized, single-blind, parallel groups, controlled study to compare levofloxacin and prulifloxacin in patients with exacerbations of COPD previously treated with different antibiotics and admitt...
    Medical condition: - Patients with acute exacerbation of COPD of possible infectious origin, previously treated with antibiotic therapy (no quinolones), without clinical improvement, and hospitalized in Internal Medi...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004659-19 Sponsor Protocol Number: BAYQ3939/15626 Start Date*: 2014-04-23
    Sponsor Name:Bayer AG
    Full Title: Randomized, double-blind, placebo-controlled, multicenter study comparing Ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus p...
    Medical condition: non-CF bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) LT (Completed) AT (Completed) CZ (Completed) PT (Completed) BG (Completed) LV (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2015-002743-33 Sponsor Protocol Number: Z7224L01 Start Date*: 2017-02-21
    Sponsor Name:Zambon S.p.A.
    Full Title: A double-blind, placebo controlled, multi-centre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled colistimethate sodium in the treatment of subjects with ...
    Medical condition: Non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) PT (Completed) NL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000325-49 Sponsor Protocol Number: CQBW251B2202 Start Date*: 2020-04-09
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, subjects and investigator blinded, placebo controlled parallel group study to assess the mode of action of QBW251 in patients with Chronic Obstructive Pulmonary Disease (COPD)
    Medical condition: Chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10029972 Obstructive airways disease (chronic) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Temporarily Halted) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-003304-41 Sponsor Protocol Number: 1397-0012 Start Date*: 2022-06-09
    Sponsor Name:Boehringer Ingelheim SComm
    Full Title: A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectas...
    Medical condition: bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) ES (Completed) HU (Completed) FR (Completed) IT (Completed) LV (Completed) CZ (Completed) DE (Completed) GR (Completed) DK (Completed) PL (Completed) PT (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023235-41 Sponsor Protocol Number: 12012.101 Start Date*: Information not available in EudraCT
    Sponsor Name:PARI Pharma GmbH
    Full Title: A comparative, randomised, two period, multi-center, cross-over 14 weeks bioequivalence study of Tobramycin PARI (T100) versus TOBI® (Novartis) in cystic fibrosis patients with bronchopulmonary chr...
    Medical condition: Cystic fibrosis with bronchopulmonary chronic Pseudomonas aeruginosa infection
    Disease: Version SOC Term Classification Code Term Level
    12.1 10011763 Cystic fibrosis lung LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-018738-27 Sponsor Protocol Number: CF2110399 Start Date*: 2010-06-02
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients with Cystic Fibrosis
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10011763 Cystic fibrosis lung LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002035-28 Sponsor Protocol Number: TBM100C2301 (TIP002) Start Date*: 2005-09-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Trial to Assess the Efficacy and Safety of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis (CF) Subjects
    Medical condition: pulmonary P aeruginosa infection in patient with cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011762 Cystic fibrosis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003446-45 Sponsor Protocol Number: TBTCS31/A5349 Start Date*: 2016-02-25
    Sponsor Name:Unidad de investigación en Tuberculosis de Barcelona
    Full Title: Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial
    Medical condition: Pulmonary tuberculosis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000827-13 Sponsor Protocol Number: A5951001 Start Date*: 2007-11-26
    Sponsor Name:Pfizer Pharmaceutical Group
    Full Title: LINEZOLID IN THE TREATMENT OF SUBJECTS WITH NOSOCOMIAL PNEUMONIA PROVEN TO BE DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS
    Medical condition: MRSA Infection - Nosocomical Pneumenia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052596 Nosocomial pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002046-31 Sponsor Protocol Number: KFL3503 Start Date*: 2016-02-15
    Sponsor Name:Mundipharma Research Limited
    Full Title: A randomised, single blind, cross-over study to compare a fixed dose combination of fluticasone propionate / formoterol fumarate (fluticasone /formoterol breath actuated inhaler (BAI)) with a fixe...
    Medical condition: Fixed airflow obstruction with elevated eosinophils
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10077006 Asthma-COPD overlap syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Prematurely Ended) ES (Completed) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003768-31 Sponsor Protocol Number: NNF18OC0052256 Start Date*: 2019-12-05
    Sponsor Name:Lungemedicinsk Forskningsenhed
    Full Title: Effects of azithromycin treatment on anti-viral immunity in patients with asthma and COPD.
    Medical condition: COPD and asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-001929-40 Sponsor Protocol Number: AZT_DSTB_BB Start Date*: 2017-11-21
    Sponsor Name:University Medical Center Groningen
    Full Title: A prospective, randomized pilot study of the immunomodulatory effects of azithromycin in adults with pulmonary tuberculosis
    Medical condition: Pulmonary tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10037440 Pulmonary tuberculosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003013-34 Sponsor Protocol Number: UOL0730 Start Date*: 2020-03-02
    Sponsor Name:University of Leicester
    Full Title: Beyond Allergic Th2 Severe Asthma
    Medical condition: T2-High and T2-Low severe asthma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10005503 Blood eosinophils LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    21.1 100000004865 10049868 Asthma exacerbation prophylaxis LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2010-023945-31 Sponsor Protocol Number: PRINA Start Date*: 2010-12-17
    Sponsor Name:AZIENDA OSPEDALIERA S. PAOLO (A.O. DI RILIEVO NAZIONALE)
    Full Title: Effect of Prasugrel sull'iperreattivita' bronchial and markers of airway inflammation in patients with chronic asthma: randomized crossover pilot study (Study PRINA).
    Medical condition: bronchial asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004351-39 Sponsor Protocol Number: FARM8MXYFL Start Date*: 2011-10-28
    Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
    Full Title: Phase II, randomized, double arm, multi-center study evaluating the efficacy and safety of azithromycin for the long term prophylactic treatment of COPD in primary antibody deficiency patients with...
    Medical condition: primary immunodefciency patients with COPD and frequent exacerbations
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10029978 Obstructive chronic bronchitis with acute exacerbation LLT
    14.1 10021428 - Immune system disorders 10013289 Disorders involving the immune mechanism LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003554 Asthma aggravated LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005097-52 Sponsor Protocol Number: 109405 Start Date*: 2007-04-25
    Sponsor Name:Adelaide & Meath Hospital [...]
    1. Adelaide & Meath Hospital
    2. Adelaide & Meath Hospital, incorporating the National Children's hospital
    Full Title: A Single-Centre, Randomised, double-blind, two month Interventional Parallel group Study Assessing the in vivo synergy of salmeterol xinafoate/fluticasone propionate (50/250 μg twice daily) via a ...
    Medical condition: Eosinophilic inflammation in the lungs of adult subjects > 18 years old who have moderate bronchial asthma.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003555 Asthma bronchial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 17:12:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA